Skip to main content

Premium on Gland Pharma shares declines significantly in grey market ahead of listing

In fact the premium has consistently been falling since the announcement of price band for its IPO in first week of November.

The share price premium of Gland Pharma in the grey market has significantly fallen ahead of the listing of shares later this week, despite the market being flooded with FII money and being traded at record high levels.

Shares are available at a premium of just Rs 6-10 in the grey market compared to its IPO price of Rs 1,500 per share, people familiar with the primary market development told Moneycontrol.



In fact, the premium has been falling consistently since the announcement of price band for its IPO in the first week of November. It was trading at a premium of Rs 200 per share just before the declaration of IPO price band, but then the premium fell to around Rs 60-70 and after closing of IPO, it further fell to Rs 35-40.

The high valuations and tepid response from investors (barring QIBs) could be some of key reasons for a decline in grey market premium.

"Uncertainty and lacked confidence from investors as a fact that 74 percent of Gland Pharma is owned by Chinese drug firm Fosun Pharma hurt local demand. Anti-Chinese sentiment due to the border dispute may have played a role in the reticence shown by domestic investors. As far as valuations are concerned even that was bit rich when compared to large pharma players in India and surprisingly we have seen huge rallies in pharma stocks in the past year which now trends low interest in new pharma entries," Prashanth Tapse, AVP Research at Mehta Equities told Moneycontrol.

"On overall basis institutional participation was also subdued compared to some other recent IPOs which is getting reflected in lower grey demand and supply before listing. Hence only high-risk long-term investors may hold rest allotted investors we advise to exit on decent listing," he said.

The pharma sector itself, especially after COVID-19 crisis, witnessed stellar rally given the huge healthcare demand. Nifty Pharma index climbed 83 percent from its March 23's low point.

The company launched its IPO during November 9-11, which was subscribed only 2.06 times. Only qualified institutional buyers helped the issue get subscribed as their reserved portion witnessed subscription of 6.4 times, while the response from retail investors (24 percent) and non-institutional investors (51 percent) was largely muted.

Gland Pharma, which is owned by China's Fosun Pharma, is expected to debut on bourses on November 20. Eligible investors are likely to get shares in their accounts by November 19 after the finalisation of basis of allotment around November 17.

The company raised Rs 6,480 crore via public issue, the second largest IPO after SBI Cards and Payment Services (Rs 10,355 crore) in 2020.

The public issue had comprised a fresh issue of Rs 1,250 crore and an offer for sale of over 3.48 crore shares by promoter and other selling shareholders.

Gland Pharma will utilise net proceeds from its fresh issue for funding incremental working capital requirements, funding capital expenditure requirements and general corporate purposes, while the promoter and selling shareholders received offer for sale money.

Source- Moneycontrol.com

Comments

Post a Comment

Popular posts from this blog

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

  Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...
Post a Comment
Read more